The AABB just updated its Ebola Toolkit and made proposed changes to the Uniform Donor Questionnaire UDQ to reflect this. Up to five (5) questions should be included in your questionnaire. What question(s) to use depends on:
- Are you in an area with NO widespread transmission?—1 question (#1)
- Are you in an area with widespread transmission?—5 questions (#1-5)
- Are you in an area post-widespread (> 4 weeks) transmission?—1 question (#1)
|Ebola Question 1: Have you ever had Ebola virus disease or infection?||q||q|
|Ebola Question 2: In the past 8 weeks, have you lived in, or traveled to, a country with widespread transmission of Ebola virus disease or infection? (Review list of affected areas, as classified by CDC) *||q||q|
|Ebola Question 3: In the past 8 weeks, have you had sexual contact with a person who has EVER had Ebola virus disease or infection?||q||q|
|Ebola Question 4: In the past 8 weeks, have you had direct exposure to body fluids (blood, urine, stool, saliva, semen, vaginal fluids or vomit) from a person who may have Ebola virus disease or infection, including a person under investigation?||q||q|
|Ebola Question 5: In the past 8 weeks, have you been notified by a public health authority that you may have been exposed to a person with Ebola virus disease or infection?||q||q|
If the response to question #1 is YES, then the donor is indefinitely deferred.
For questions 2-5, there is an 8-week deferral.
In areas with no widespread transmission, self-deferral of donors with a history of Ebola infection should be adequate, only question #1 is required. If there is widespread transmission, questions #2-5 should be added. Four (4) weeks after widespread transmission stops, revert back to using question #1 only.
These can be easily added to the donor questionnaire in Medinfo blood donor module.
- AABB v2.1 DHQ and Flowcharts Modified for Ebola Risk, March 2021, AABB, Bethesda, MD, USA
- AABB Ebola Toolkit, Revised May 2020, Bethesda, MD, USA
- Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus, Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research, January 2017